{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:31:15Z","timestamp":1793579475537,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiorenal risk in type 2 diabetes. However, the effect of combining these drugs remains uncertain. This systematic review aimed to evaluate the potential effectiveness and safety of combination therapy compared with monotherapy in individuals with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We systematically searched PubMed and Embase from inception to 1 May 2025 for cohort studies comparing the effect of combination therapy with SGLT2 inhibitor or GLP-1 RA monotherapy on (cardiovascular) mortality and cardiovascular or kidney endpoints in individuals with type 2 diabetes. Studies enrolling individuals with type 1 diabetes or a maximum follow-up of less than 1 year were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE). Secondary outcomes included all-cause mortality, cardiovascular mortality, hospitalisation for heart failure, a kidney composite endpoint and serious adverse events. Risk of bias was assessed with ROBINS-I. Risk ratios (RRs) and 95% CIs were pooled in random effects meta-analyses. Certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 18 cohort studies (1,164,774 participants). In cohort studies, combination therapy was associated with a lower risk of MACE (RR 0.56 [95% CI 0.43, 0.71]; low certainty of evidence) and the kidney composite endpoint (RR 0.48 [95% CI 0.32, 0.73]; very low certainty of evidence) relative to SGLT2 inhibitor or GLP-1 RA monotherapy. Combination therapy was also associated with a lower risk of all-cause mortality (RR 0.50 [95% CI 0.40, 0.63]; low certainty of evidence), cardiovascular mortality (RR 0.26 [95% CI 0.16, 0.43]; low certainty of evidence) and hospitalisation for heart failure (RR 0.67 [95% CI 0.64, 0.71]; moderate certainty of evidence). Although safety data could not be pooled due to lack of events, no differences were observed in the risk of severe hypoglycaemia, diabetic ketoacidosis, genitourinary infections and gastrointestinal side effects. No data were reported on the risk of serious adverse events or major adverse limb events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>Observational studies suggest that combining an SGLT2 inhibitor and a GLP-1 RA in type 2 diabetes may lower the risk of MACE, all-cause and cardiovascular mortality, hospitalisation for heart failure and kidney composite endpoints compared with monotherapy with either drug. Of course, residual confounding cannot be overcome but results support the need for future randomised trials of combined vs monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO registration no. CRD42024532383<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-025-06565-6","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:41:38Z","timestamp":1761057698000},"page":"36-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-5937","authenticated-orcid":false,"given":"Julia M. T.","family":"Colombijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-8923","authenticated-orcid":false,"given":"Jan F.","family":"de Leijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-5223","authenticated-orcid":false,"given":"Frank L. J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3276-6428","authenticated-orcid":false,"given":"Marianne C.","family":"Verhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2894-6124","authenticated-orcid":false,"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-4566","authenticated-orcid":false,"given":"Robin W. M.","family":"Vernooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2870-482X","authenticated-orcid":false,"given":"Thomas T.","family":"van Sloten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"10467","key":"6565_CR1","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","volume":"404","author":"B Zhou","year":"2024","unstructured":"Zhou B, Rayner AW, Gregg EW et al (2024) Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 404(10467):2077\u20132093. https:\/\/doi.org\/10.1016\/S0140-6736(24)02317-1","journal-title":"Lancet"},{"key":"6565_CR2","doi-asserted-by":"publisher","unstructured":"(2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397):203\u2013234. https:\/\/doi.org\/10.1016\/s0140-6736(23)01301-6","DOI":"10.1016\/s0140-6736(23)01301-6"},{"issue":"2_suppl","key":"6565_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryd\u00e9n L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26(2_suppl):25\u201332. https:\/\/doi.org\/10.1177\/2047487319878371","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"6565_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny HC, Abel ED (2019) Heart failure in type 2 diabetes mellitus. Circ Res 124(1):121\u2013141. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311371","journal-title":"Circ Res"},{"issue":"1","key":"6565_CR5","doi-asserted-by":"publisher","first-page":"e0147329","DOI":"10.1371\/journal.pone.0147329","volume":"11","author":"M Narres","year":"2016","unstructured":"Narres M, Claessen H, Droste S et al (2016) The incidence of end-stage renal disease in the diabetic (Compared to the Non-Diabetic) population: a systematic review. PLOS ONE 11(1):e0147329. https:\/\/doi.org\/10.1371\/journal.pone.0147329","journal-title":"PLOS ONE"},{"issue":"2","key":"6565_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6(2):148\u2013158. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"6565_CR7","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381:e074068. https:\/\/doi.org\/10.1136\/bmj-2022-074068","journal-title":"BMJ"},{"issue":"5","key":"6565_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L et al (2023) American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm & #x2013; 2023 update. Endocr Pract 29(5):305\u2013340. https:\/\/doi.org\/10.1016\/j.eprac.2023.02.001","journal-title":"Endocr Pract"},{"issue":"12","key":"6565_CR9","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12):2461\u20132498. https:\/\/doi.org\/10.1007\/s00125-018-4729-5","journal-title":"Diabetologia"},{"issue":"Supplement_1","key":"6565_CR10","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee (2023) 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care 47(Supplement_1):S179\u2013S218. https:\/\/doi.org\/10.2337\/dc24-S010","journal-title":"Diabetes Care"},{"issue":"5, Supplement","key":"6565_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN et al (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102(5, Supplement):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"issue":"39","key":"6565_CR12","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"issue":"3","key":"6565_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jcjd.2020.09.005","volume":"45","author":"RM Goldenberg","year":"2021","unstructured":"Goldenberg RM, Ahooja V, Clemens KK, Gilbert JD, Poddar M, Verma S (2021) Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes. Can J Diabetes 45(3):291\u2013302. https:\/\/doi.org\/10.1016\/j.jcjd.2020.09.005","journal-title":"Can J Diabetes"},{"issue":"17","key":"6565_CR14","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139(17):2022\u20132031. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"issue":"2","key":"6565_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle Katherine R, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"1","key":"6565_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-024-02192-4","volume":"23","author":"A Ahmad","year":"2024","unstructured":"Ahmad A, Sabbour H (2024) Effectiveness and safety of the combination of sodium\u2013glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovasc Diabetol 23(1):99. https:\/\/doi.org\/10.1186\/s12933-024-02192-4","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"6565_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55524-w","volume":"9","author":"M Castellana","year":"2019","unstructured":"Castellana M, Cignarelli A, Brescia F et al (2019) Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Sci Rep 9(1):1\u20138","journal-title":"Sci Rep"},{"issue":"1","key":"6565_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","volume":"22","author":"P Gourdy","year":"2023","unstructured":"Gourdy P, Darmon P, Dievart F, Halimi J-M, Guerci B (2023) Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol 22(1):79. https:\/\/doi.org\/10.1186\/s12933-023-01798-4","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"6565_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA et al (2024) Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 12(8):545\u2013557. https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"6565_CR20","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/circulationaha.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L et al (2024) Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation 150(22):1781\u20131790. https:\/\/doi.org\/10.1161\/circulationaha.124.071689","journal-title":"Circulation"},{"issue":"1","key":"6565_CR21","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.diabet.2024.101594","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ (2025) Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies. Diabetes Metab 51(1):101594. https:\/\/doi.org\/10.1016\/j.diabet.2024.101594","journal-title":"Diabetes Metab"},{"issue":"10","key":"6565_CR22","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.2337\/dc19-1350","volume":"43","author":"SA Jabbour","year":"2020","unstructured":"Jabbour SA, Fr\u00edas JP, Ahmed A et al (2020) Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43(10):2528\u20132536. https:\/\/doi.org\/10.2337\/dc19-1350","journal-title":"Diabetes Care"},{"issue":"10","key":"6565_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.7326\/0003-4819-154-10-201105170-00008","volume":"154","author":"TJ VanderWeele","year":"2011","unstructured":"VanderWeele TJ, Knol MJ (2011) Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann Int Med 154(10):680\u2013683. https:\/\/doi.org\/10.7326\/0003-4819-154-10-201105170-00008","journal-title":"Ann Int Med"},{"key":"6565_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"8","key":"6565_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.amjmed.2024.04.032","volume":"137","author":"D Garc\u00eda-Vega","year":"2024","unstructured":"Garc\u00eda-Vega D, Cinza-Sanjurjo S, Eiras S, Gonz\u00e1lez-Juanatey JR (2024) Combined sodium-glucose-transporters inhibitors and glucagon-like-peptide receptor agonist compared with monotherapy improves long-term survival: a real-world registry. Am J Med 137(8):761-769.e761. https:\/\/doi.org\/10.1016\/j.amjmed.2024.04.032","journal-title":"Am J Med"},{"key":"6565_CR26","doi-asserted-by":"publisher","first-page":"132611","DOI":"10.1016\/j.ijcard.2024.132611","volume":"418","author":"Y Horiuchi","year":"2025","unstructured":"Horiuchi Y, Wettersten N, Asami M et al (2025) Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure. Int J Cardiol 418:132611. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132611","journal-title":"Int J Cardiol"},{"key":"6565_CR27","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"4","key":"6565_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"6565_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY (2025) Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol 24(1):177. https:\/\/doi.org\/10.1186\/s12933-025-02737-1","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"6565_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","volume":"143","author":"CV Dave","year":"2021","unstructured":"Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E (2021) Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation 143(8):770\u2013779. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047965","journal-title":"Circulation"},{"issue":"2","key":"6565_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.numecd.2016.11.007","volume":"27","author":"JJ Gorgojo-Mart\u00ednez","year":"2017","unstructured":"Gorgojo-Mart\u00ednez JJ, Serrano-Moreno C, Sanz-Velasco A, Feo-Ortega G, Almod\u00f3var-Ruiz F (2017) Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes. Nutr Metab Cardiovasc Diseases 27(2):129\u2013137. https:\/\/doi.org\/10.1016\/j.numecd.2016.11.007","journal-title":"Nutr Metab Cardiovasc Diseases"},{"issue":"6","key":"6565_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2337\/dc19-2535","volume":"43","author":"MH Jensen","year":"2020","unstructured":"Jensen MH, Kjolby M, Hejlesen O, Jakobsen PE, Vestergaard P (2020) Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: a cohort study of all Danish users. Diabetes Care 43(6):1209\u20131218. https:\/\/doi.org\/10.2337\/dc19-2535","journal-title":"Diabetes Care"},{"issue":"2","key":"6565_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jdi.14361","volume":"16","author":"JY Jhu","year":"2025","unstructured":"Jhu JY, Fang YW, Huang CY, Liou HH, Chen MT, Tsai MH (2025) Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real-world evidence. J Diabetes Investig 16(2):204\u2013214. https:\/\/doi.org\/10.1111\/jdi.14361","journal-title":"J Diabetes Investig"},{"issue":"6","key":"6565_CR34","doi-asserted-by":"publisher","first-page":"147916412312228","DOI":"10.1177\/14791641231222837","volume":"20","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Toyoda M, Tone A et al (2023) Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication. Diab Vasc Dis Res 20(6):14791641231222836. https:\/\/doi.org\/10.1177\/14791641231222837","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"6565_CR35","doi-asserted-by":"publisher","first-page":"e023489","DOI":"10.1161\/JAHA.121.023489","volume":"11","author":"KTK Lau","year":"2022","unstructured":"Lau KTK, Wong CKH, Au ICH et al (2022) Switching to versus addition of incretin-based drugs among patients with type 2 diabetes taking sodium-glucose cotransporter-2 inhibitors. J Am Heart Assoc 11(7):e023489. https:\/\/doi.org\/10.1161\/JAHA.121.023489","journal-title":"J Am Heart Assoc"},{"key":"6565_CR36","doi-asserted-by":"publisher","first-page":"133229","DOI":"10.1016\/j.ijcard.2025.133229","volume":"431","author":"T Liu","year":"2025","unstructured":"Liu T, Fan Z, Li Y, Xiao B, He C (2025) Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: a propensity score-matched cohort study. Int J Cardiol 431:133229. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133229","journal-title":"Int J Cardiol"},{"key":"6565_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.amjcard.2022.07.012","volume":"181","author":"PD Lopez","year":"2022","unstructured":"Lopez PD, Bhatia K, Bohra C, Mahmood K, Baruch L, Eng C (2022) Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure. Am J Cardiol 181:87\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2022.07.012","journal-title":"Am J Cardiol"},{"key":"6565_CR38","doi-asserted-by":"publisher","unstructured":"Luo Z, Chou OH-I, Ng ZMW et al (2023) Compare SGLT2I versus non-SGLT2I users in type-2 diabetic mellitus patients on GLP-1 receptor agonist: a population-based and machine learning causal inference analysis. medRxiv: 2023.2011.2006.23298185. https:\/\/doi.org\/10.1101\/2023.11.06.23298185","DOI":"10.1101\/2023.11.06.23298185"},{"issue":"1","key":"6565_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","volume":"23","author":"R Marfella","year":"2024","unstructured":"Marfella R, Prattichizzo F, Sardu C et al (2024) GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol 23(1):10. https:\/\/doi.org\/10.1186\/s12933-023-02118-6","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"6565_CR40","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B et al (2024) GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail 12(11):1814\u20131826. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.006","journal-title":"JACC Heart Fail"},{"issue":"10","key":"6565_CR41","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/dom.15185","volume":"25","author":"DR Riley","year":"2023","unstructured":"Riley DR, Essa H, Austin P et al (2023) All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab 25(10):2897\u20132909. https:\/\/doi.org\/10.1111\/dom.15185","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6565_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12933-023-01829-0","volume":"22","author":"M Schechter","year":"2023","unstructured":"Schechter M, Melzer Cohen C, Fishkin A et al (2023) Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovasc Diabetol 22(1):126. https:\/\/doi.org\/10.1186\/s12933-023-01829-0","journal-title":"Cardiovasc Diabetol"},{"key":"6565_CR43","doi-asserted-by":"publisher","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H et al (2024) Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ 385:e078242. https:\/\/doi.org\/10.1136\/bmj-2023-078242","journal-title":"BMJ"},{"issue":"4","key":"6565_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/dc21-1113","volume":"45","author":"AK Wright","year":"2022","unstructured":"Wright AK, Carr MJ, Kontopantelis E et al (2022) Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 45(4):909\u2013918. https:\/\/doi.org\/10.2337\/dc21-1113","journal-title":"Diabetes Care"},{"key":"6565_CR45","doi-asserted-by":"publisher","first-page":"1028486","DOI":"10.3389\/fphys.2022.1028486","volume":"13","author":"L Du","year":"2022","unstructured":"Du L, Qin J, Wang D et al (2022) Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Front Physiol 13:1028486. https:\/\/doi.org\/10.3389\/fphys.2022.1028486","journal-title":"Front Physiol"},{"issue":"Supplement_2","key":"6565_CR46","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R (2016) SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39(Supplement_2):S165\u2013S171. https:\/\/doi.org\/10.2337\/dcS15-3006","journal-title":"Diabetes Care"},{"issue":"2","key":"6565_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2337\/dc20-2604","volume":"44","author":"RA Scholtes","year":"2020","unstructured":"Scholtes RA, Muskiet MHA, van Baar MJB et al (2020) Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care 44(2):440\u2013447. https:\/\/doi.org\/10.2337\/dc20-2604","journal-title":"Diabetes Care"},{"issue":"16","key":"6565_CR48","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3390\/ijerph16162965","volume":"16","author":"A Tentolouris","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N (2019) SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 16(16):2965. https:\/\/doi.org\/10.3390\/ijerph16162965","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"6565_CR49","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci 17(8):2050\u20132068. https:\/\/doi.org\/10.7150\/ijbs.59965","journal-title":"Int J Biol Sci"},{"issue":"4","key":"6565_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dci23-0041","volume":"47","author":"N Sattar","year":"2024","unstructured":"Sattar N, Presslie C, Rutter MK, McGuire DK (2024) Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity. Diabetes Care 47(4):531\u2013543. https:\/\/doi.org\/10.2337\/dci23-0041","journal-title":"Diabetes Care"},{"issue":"4","key":"6565_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/s2213-8587(24)00363-2","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, Lee MMY (2025) Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions. Lancet Diabetes Endocrinol 13(4):347\u2013354. https:\/\/doi.org\/10.1016\/s2213-8587(24)00363-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6565_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","volume":"15","author":"PT von Hippel","year":"2015","unstructured":"von Hippel PT (2015) The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol 15(1):35. https:\/\/doi.org\/10.1186\/s12874-015-0024-z","journal-title":"BMC Med Res Methodol"},{"key":"6565_CR53","unstructured":"Deeks JJ, Higgins JPT, Altman DG, McKenzie JE, Veroniki AA (eds) (2024) Chapter 10: analysing data and undertaking meta-analyses [updated November 2024]. In: Higgins JPT, Thomas J, Chandler J et al (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, London"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06565-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:14:27Z","timestamp":1765185267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06565-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6565"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06565-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The dataset is available in the ESM\n                      \n                      file.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Code\/syntax is available in the ESM\n                      \n                      file.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JC, MV and RV are supported by grant 2020B008 RECONNEXT from the Dutch CardioVascular Alliance, an initiative supported by the Dutch Heart Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DvR reports receiving personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and MSD, outside this manuscript. NS reported receiving personal fees from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer and Roche, and research grants from AstraZeneca, Boehringer Ingelheim, Novartis and Roche, outside this manuscript. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"JC, JdL, RV and TvS designed the study. JC and JdL acquired the data. JC performed the data analysis and drafted the manuscript. JC and JdL drafted the tables, figures and graphical abstract. All authors contributed to the interpretation of the data, critically revised the manuscript, provided intellectual input and approved the final version to be published. JC and TvS are responsible for the integrity of the work as a whole.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}